+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Autoimmune Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4895982
  • Report
  • June 2020
  • Region: Global
  • 114 Pages
  • Mordor Intelligence


  • Abbvie
  • Amgen Inc.
  • Astrazeneca Plc
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
The autoimmune treatment market is expected to grow with a CAGR of 4.2%, over the forecast period. The major factor attributing to the growth of the autoimmune treatment market is surge in prevalence of autoimmune diseases. According to NIH (National Institutes of Health) up to 23.5 million Americans have an autoimmune disease and the prevalance is increasing. Scientists have identified 80-100 various autoimmune diseases and assume at least 40 other diseases of having an autoimmune basis. The other factors that play a major role in taking the autoimmune treatment market to the next level are increasing investments in research and development of drugs for autoimmune diseases, technological advancements in diagnosis and awareness of the therapy. Rising government initiatives for regulating these diseases is also helping the growth of the market. However, higher costs of the therapeutics and low medical insurance coverage are constraining the market growth.

Key Market Trends

Rheumatic Disease segment is Expected to Hold Large Market Share
  • The rheumatic disease segment is expected to dominate the market owing to the rising cases of diseases. Rheumatic diseases are described by swelling that affects the connecting structures of the body, mostly the joints, sometimes the tendons, ligaments, bones, and muscles.
  • The therapeutics for rheumatoid disease holds the significant share and expected to remain assertive during the forecast period, due to the rising geriatric population, increasing number of pipeline drugs and the increasing cases of arthritis, fibromyalgia, systemic lupus erythematosus, gout and others, and varied range and availability of progressive therapeutics for the treatment of these diseases.
  • In 2018, according to RheumatoidArthritis.org, around 1.3 million Americans were affected by Rheumatoid arthritis, and the number is increasing every year, which is a driving factor for the autoimmune treatment market.

North America Dominates the Market and Expected to do same in the Forecast Period

North America is expected to dominate the overall autoimmune treatment market, throughout the forecast period. This is due to factors such as the rising incidence and prevalence of autoimmune diseases like arthritis, lupus, multiple sclerosis, in the country. In the North America region, the United States holds the largest market share due to growing personal expenditure on healthcare. The healthcare commerce in the province is developing at a quick stride, resulting in the progress of the North America Autoimmune treatment market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.

Competitive Landscape

The autoimmune treatment market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AbbVie, Amgen, Johnson & Johnson, Eli Lilly & Co., Pfizer, F. Hoffmann-La Roche AG, Astrazeneca Plc and Bristol-Myers Squibb Co.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Abbvie
  • Amgen Inc.
  • Astrazeneca Plc
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Prevalence of Autoimmune Diseases
4.2.2 Increasing Investments in Research and development
4.2.3 Advancements in Diagnostic Methods
4.3 Market Restraints
4.3.1 Higher Cost of Therapeutics
4.3.2 Low Medical Insurance Coverage for Autoimmune Diseases
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Indication
5.1.1 Rheumatic Disease
5.1.2 Diabetes
5.1.3 Multiple Sclerosis
5.1.4 Inflammatory Bowel Disease
5.1.5 Other Indications
5.2 By Drug Class
5.2.1 Anti-Inflammatory
5.2.2 Anti-Hyperglycemics
5.2.3 NSAIDs
5.2.4 Interferons
5.2.5 Other Drugs
5.3 By Sales Channel
5.3.1 Hospital Pharmacy
5.3.2 Online
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Abbvie
6.1.2 Amgen Inc.
6.1.3 Johnson & Johnson
6.1.4 Eli Lilly and Company
6.1.5 Pfizer Inc.
6.1.6 F. Hoffmann-La Roche AG
6.1.7 Astrazeneca Plc
6.1.8 Bristol-Myers Squibb Co.
6.1.9 Lupin Limited
6.1.10 GlaxoSmithKline Plc
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbvie
  • Amgen Inc.
  • Johnson & Johnson
  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Astrazeneca Plc
  • Bristol-Myers Squibb Co.
  • Lupin Limited
  • GlaxoSmithKline Plc
Note: Product cover images may vary from those shown